QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.47 (+0.71%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.88 (-0.93%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.26%)
GE   110.85 (+0.84%)
DIS   79.89 (-0.20%)
AMC   7.57 (-4.30%)
PFE   32.11 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.47 (+0.71%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.88 (-0.93%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.26%)
GE   110.85 (+0.84%)
DIS   79.89 (-0.20%)
AMC   7.57 (-4.30%)
PFE   32.11 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.47 (+0.71%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.88 (-0.93%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.26%)
GE   110.85 (+0.84%)
DIS   79.89 (-0.20%)
AMC   7.57 (-4.30%)
PFE   32.11 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.47 (+0.71%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.88 (-0.93%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.26%)
GE   110.85 (+0.84%)
DIS   79.89 (-0.20%)
AMC   7.57 (-4.30%)
PFE   32.11 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
NASDAQ:FNCH

Finch Therapeutics Group (FNCH) Stock Forecast, Price & News

$5.48
-0.06 (-1.08%)
(As of 09/27/2023 ET)
Compare
Today's Range
$5.14
$5.55
50-Day Range
$5.54
$9.19
52-Week Range
$5.14
$60.00
Volume
3,853 shs
Average Volume
17,406 shs
Market Capitalization
$8.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$210.00

Finch Therapeutics Group MarketRank™ Forecast

Analyst Rating
0.00 Rating Score
Upside/​Downside
3,732.1% Upside
$210.00 Price Target
Short Interest
Bearish
5.05% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.44mentions of Finch Therapeutics Group in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($30.98) to ($20.59) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.56 out of 5 stars


FNCH stock logo

About Finch Therapeutics Group (NASDAQ:FNCH) Stock

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524, FIN-525, and other microbiome product candidates for inflammatory bowel disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.

FNCH Price History

FNCH Stock News Headlines

Finch Therapeutics Group (NASDAQ:FNCH) Stock Price Down 2.6%
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
8-K: Finch Therapeutics Group, Inc.
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
FINCH THERAPEUTICS GROUP INC
Finch Therapeutics Group (FNCH) Gets a Buy from H.C. Wainwright
FNCH Finch Therapeutics Group, Inc.
Finch Therapeutics To Reduce Workforce - Quick Facts
See More Headlines
Receive FNCH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Finch Therapeutics Group and its competitors with MarketBeat's FREE daily newsletter.

FNCH Company Calendar

Last Earnings
8/10/2023
Today
9/27/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FNCH
Fax
N/A
Employees
18
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$210.00
High Stock Price Forecast
$210.00
Low Stock Price Forecast
$210.00
Forecasted Upside/Downside
+3,732.1%
Consensus Rating
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Net Income
$-114,650,000.00
Net Margins
-25,084.36%
Pretax Margin
-56,019.37%

Debt

Sales & Book Value

Annual Sales
$860,000.00
Book Value
$60.01 per share

Miscellaneous

Free Float
884,000
Market Cap
$8.77 million
Optionable
Not Optionable
Beta
0.17
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Matthew P. Blischak J.D.
    Chief Exec. Officer
  • Mr. Lance Thibault CPA (Age 57)
    CPA, Chief Financial Officer
  • Mr. James S. Sigler MBA (Age 62)
    Exec. VP of CMC













FNCH Stock - Frequently Asked Questions

What is Finch Therapeutics Group's stock price forecast for 2023?

0 Wall Street research analysts have issued 12 month target prices for Finch Therapeutics Group's stock. Their FNCH share price forecasts range from $210.00 to $210.00. On average, they predict the company's share price to reach $210.00 in the next twelve months. This suggests a possible upside of 3,732.1% from the stock's current price.
View analysts price targets for FNCH
or view top-rated stocks among Wall Street analysts.

How have FNCH shares performed in 2023?

Finch Therapeutics Group's stock was trading at $14.40 at the start of the year. Since then, FNCH shares have decreased by 61.9% and is now trading at $5.48.
View the best growth stocks for 2023 here
.

Are investors shorting Finch Therapeutics Group?

Finch Therapeutics Group saw a increase in short interest in September. As of September 15th, there was short interest totaling 28,500 shares, an increase of 27.2% from the August 31st total of 22,400 shares. Based on an average daily trading volume, of 10,500 shares, the days-to-cover ratio is presently 2.7 days. Currently, 5.1% of the company's shares are short sold.
View Finch Therapeutics Group's Short Interest
.

When is Finch Therapeutics Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our FNCH earnings forecast
.

How were Finch Therapeutics Group's earnings last quarter?

Finch Therapeutics Group, Inc. (NASDAQ:FNCH) posted its earnings results on Thursday, August, 10th. The company reported ($4.33) earnings per share for the quarter, beating analysts' consensus estimates of ($4.51) by $0.18. Finch Therapeutics Group had a negative net margin of 25,084.36% and a negative trailing twelve-month return on equity of 115.37%.

When did Finch Therapeutics Group's stock split?

Finch Therapeutics Group shares reverse split before market open on Monday, June 12th 2023. The 1-30 reverse split was announced on Monday, June 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

When did Finch Therapeutics Group IPO?

(FNCH) raised $101 million in an IPO on Friday, March 19th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. BofA Securities, Jefferies and Evercore ISI acted as the underwriters for the IPO.

What is Finch Therapeutics Group's stock symbol?

Finch Therapeutics Group trades on the NASDAQ under the ticker symbol "FNCH."

Who are Finch Therapeutics Group's major shareholders?

Finch Therapeutics Group's stock is owned by a number of retail and institutional investors. Top institutional investors include Baupost Group LLC MA (4.21%) and Lake Street Advisors Group LLC (1.32%). Insiders that own company stock include Jeffery A Smisek, Marc Blaustein and Nicholas Haft.
View institutional ownership trends
.

How do I buy shares of Finch Therapeutics Group?

Shares of FNCH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Finch Therapeutics Group's stock price today?

One share of FNCH stock can currently be purchased for approximately $5.48.

How much money does Finch Therapeutics Group make?

Finch Therapeutics Group (NASDAQ:FNCH) has a market capitalization of $8.77 million and generates $860,000.00 in revenue each year. The company earns $-114,650,000.00 in net income (profit) each year or ($86.6130) on an earnings per share basis.

How can I contact Finch Therapeutics Group?

The official website for the company is www.finchtherapeutics.com. The company can be reached via phone at 617-229-6499 or via email at ir@finchtherapeutics.com.

This page (NASDAQ:FNCH) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -